{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:25:27Z","timestamp":1792794327365,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"36","license":[{"start":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T00:00:00Z","timestamp":1628985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"British Heart Foundation Clinical Research Training Fellowship","award":["FS\/18\/14\/33330"],"award-info":[{"award-number":["FS\/18\/14\/33330"]}],"id":[{"id":"https:\/\/ror.org\/02wdwnk04","id-type":"ROR","asserted-by":"crossref"}]},{"name":"British Heart Foundation Centre of Research Excellence","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}],"id":[{"id":"https:\/\/ror.org\/02wdwnk04","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on \u2018apparent resistant hypertension\u2019 in patients with HFpEF in the PARAGON-HF trial, which compared the effect of sacubitril\u2013valsartan with valsartan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this post hoc analysis, patients were categorized according to systolic blood pressure at the end of the valsartan run-in (n\u2009=\u20094795). \u2018Apparent resistant hypertension\u2019 was defined as systolic blood pressure \u2265140\u2009mmHg (\u2265135\u2009mmHg if diabetes) despite treatment with valsartan, a calcium channel blocker, and a diuretic. \u2018Apparent mineralocorticoid receptor antagonist (MRA)-resistant\u2019 hypertension was defined as systolic blood pressure \u2265140\u2009mmHg (\u2265135\u2009mmHg if diabetes) despite the above treatments and an MRA. The primary outcome in the PARAGON-HF trial was a composite of total hospitalizations for heart failure and death from cardiovascular causes. We examined clinical endpoints and the safety of sacubitril\u2013valsartan according to the hypertension category. We also examined reductions in blood pressure from the end of valsartan run-in to Weeks 4 and 16 after randomization. Overall, 731 patients (15.2%) had apparent resistant hypertension and 135 (2.8%) had apparent MRA-resistant hypertension. The rate of the primary outcome was higher in patients with apparent resistant hypertension [17.3; 95% confidence interval (CI) 15.6\u201319.1 per 100 person-years] compared to those with a controlled systolic blood pressure (13.4; 12.7\u201314.3 per 100 person-years), with an adjusted rate ratio of 1.28 (95% CI 1.05\u20131.57). The reduction in systolic blood pressure at Weeks 4 and 16, respectively, was greater with sacubitril\u2013valsartan vs. valsartan in patients with apparent resistant hypertension [\u22124.8 (\u22127.0 to \u22122.5) and 3.9 (\u22126.6 to \u22121.3) mmHg] and apparent MRA-resistant hypertension [\u22128.8 (\u221214.0 to \u22123.5) and \u22126.3 (\u221212.5 to \u22120.1) mmHg]. The proportion of patients with apparent resistant hypertension achieving a controlled systolic blood pressure by Week 16 was 47.9% in the sacubitril\u2013valsartan group and 34.3% in the valsartan group [adjusted odds ratio (OR) 1.78, 95% CI 1.30\u20132.43]. In patients with apparent MRA-resistant hypertension, the respective proportions were 43.6% vs. 28.4% (adjusted OR 2.63, 95% CI 1.18\u20135.89).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sacubitril\u2013valsartan may be useful in treating apparent resistant hypertension in patients with HFpEF, even in those who continue to have an elevated blood pressure despite treatment with at least four antihypertensive drug classes, including an MRA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>PARAGON-HF: ClinicalTrials.gov Identifier NCT01920711.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab499","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T15:11:31Z","timestamp":1626448291000},"page":"3741-3752","source":"Crossref","is-referenced-by-count":147,"title":["Sacubitril\u2013valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-1271","authenticated-orcid":false,"given":"Alice M","family":"Jackson","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5317","authenticated-orcid":false,"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1308-4963","authenticated-orcid":false,"given":"Inder S","family":"Anand","sequence":"additional","affiliation":[{"name":"University of Minnesota , Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Dirk","family":"D\u00fcngen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charite\u0301 \u2013 Universita\u0308tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S P","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Center Singapore and Duke\u2013National University of Singapore , Singapore, Singapore"},{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-6316","authenticated-orcid":false,"given":"Marty P","family":"Lefkowitz","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals , East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Linssen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Group Twente , Almelo and Hengelo, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-4482","authenticated-orcid":false,"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Heart and Vascular Theme, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-6779","authenticated-orcid":false,"given":"Aldo P","family":"Maggioni","sequence":"additional","affiliation":[{"name":"Maria Cecilia Hospital, GVM Care & Research , Cotignola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Institut de Cardiologie de Montr\u00e9al, Universit\u00e9 de Montr\u00e9al , Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-8862","authenticated-orcid":false,"given":"Jose F K","family":"Saraiva","sequence":"additional","affiliation":[{"name":"Disciplina de Cardiologia Faculdade de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica de Campinas , Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Cardiology Division, Cardiovascular Department, Hospital Papa Giovanni XXIII , Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[{"name":"Minneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota , Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4757-9051","authenticated-orcid":false,"given":"Magnus O","family":"Wijkman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Department of Health, Medicine and Caring Sciences, Link\u00f6ping University, Norrk\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-8628","authenticated-orcid":false,"given":"Mehmet B","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nara Medical University , Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Zile","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina and the Ralph H. Johnson Department of Veterans Affairs Medical Center , Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,15]]},"reference":[{"key":"2022102515343604200_ehab499-B1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.hfc.2019.06.007","article-title":"Hypertension and heart failure","volume":"15","author":"Slivnick","year":"2019","journal-title":"Heart Fail Clin"},{"key":"2022102515343604200_ehab499-B2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-med-041316-090654","article-title":"Heart failure with preserved ejection fraction","volume":"69","author":"Gladden","year":"2018","journal-title":"Annu Rev Med"},{"key":"2022102515343604200_ehab499-B3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10741-018-9698-8","article-title":"The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?","volume":"23","author":"Tadic","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2022102515343604200_ehab499-B4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/HCO.0000000000000634","article-title":"Managing hypertension in patients with heart failure","volume":"34","author":"Gupta","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"2022102515343604200_ehab499-B5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/jama.300.4.431","article-title":"Heart failure with preserved ejection fraction: treat now by treating comorbidities","volume":"300","author":"Shah","year":"2008","journal-title":"JAMA"},{"key":"2022102515343604200_ehab499-B6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ajh\/hpx210","article-title":"Spironolactone and resistant hypertension in heart failure with preserved ejection fraction","volume":"31","author":"Rossignol","year":"2018","journal-title":"Am J Hypertens"},{"key":"2022102515343604200_ehab499-B7","doi-asserted-by":"crossref","first-page":"e114958","DOI":"10.1371\/journal.pone.0114958","article-title":"The prevalence and prognosis of resistant hypertension in patients with heart failure","volume":"9","author":"Jin","year":"2014","journal-title":"PLoS One"},{"key":"2022102515343604200_ehab499-B8","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2022102515343604200_ehab499-B9","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102515343604200_ehab499-B10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"2022102515343604200_ehab499-B11","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"2022102515343604200_ehab499-B12","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102515343604200_ehab499-B13","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102515343604200_ehab499-B14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cjca.2020.02.083","article-title":"Hypertension Canada\u2019s 2020 evidence review and guidelines for the management of resistant hypertension","volume":"36","author":"Hiremath","year":"2020","journal-title":"Can J Cardiol"},{"key":"2022102515343604200_ehab499-B15","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2022102515343604200_ehab499-B16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2022102515343604200_ehab499-B17","doi-asserted-by":"crossref","first-page":"e004962","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2022102515343604200_ehab499-B18","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.117.033065","article-title":"Comparison of time-to-first event and recurrent-event methods in randomized clinical trials","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"key":"2022102515343604200_ehab499-B19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.1535","article-title":"Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction","volume":"21","author":"Shen","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102515343604200_ehab499-B20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2022102515343604200_ehab499-B21","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2022102515343604200_ehab499-B22","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102515343604200_ehab499-B23","doi-asserted-by":"crossref","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2022102515343604200_ehab499-B24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102515343604200_ehab499-B25","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"2022102515343604200_ehab499-B26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.99.1.258","article-title":"Noncardiogenic pulmonary edema complicating massive diltiazem overdose","volume":"99","author":"Humbert","year":"1991","journal-title":"Chest"},{"key":"2022102515343604200_ehab499-B27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1074248417693379","article-title":"The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: a meta-analysis of randomized controlled trials","volume":"22","author":"Zhao","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2022102515343604200_ehab499-B28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension"},{"key":"2022102515343604200_ehab499-B29","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehv142","article-title":"Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials","volume":"36","author":"Bavishi","year":"2015","journal-title":"Eur Heart J"},{"key":"2022102515343604200_ehab499-B30","first-page":"296","article-title":"The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects","volume":"11","author":"Dessi-Fulgheri","year":"1998","journal-title":"J Nephrol"},{"key":"2022102515343604200_ehab499-B31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10741-011-9249-z","article-title":"The paradox of low BNP levels in obesity","volume":"17","author":"Clerico","year":"2012","journal-title":"Heart Fail Rev"},{"key":"2022102515343604200_ehab499-B32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2013.03.038","article-title":"Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile","volume":"62","author":"Neeland","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022102515343604200_ehab499-B33","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102515343604200_ehab499-B34","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/HYPERTENSIONAHA.120.16277","article-title":"Pulse pressure, prognosis, and influence of sacubitril\/valsartan in heart failure with preserved ejection fraction","volume":"77","author":"Suzuki","year":"2021","journal-title":"Hypertension"},{"key":"2022102515343604200_ehab499-B35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Hear Fail"},{"key":"2022102515343604200_ehab499-B36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2022102515343604200_ehab499-B37","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41366-020-0563-1","article-title":"Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction","volume":"44","author":"Mandviwala","year":"2020","journal-title":"Int J Obes"},{"key":"2022102515343604200_ehab499-B38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","article-title":"High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis","volume":"100","author":"Tomaszewski","year":"2014","journal-title":"Heart"},{"key":"2022102515343604200_ehab499-B39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/ehjcvp\/pvaa071","article-title":"Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography\u2013tandem mass spectrometry-based urine analysis","volume":"7","author":"Simpson","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022102515343604200_ehab499-B40","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/ehf2.13284","article-title":"Urinary drug metabolite testing in chronic heart failure patients indicates high levels of adherence with life-prolonging therapies","volume":"8","author":"Sweeney","year":"2021","journal-title":"ESC Heart Fail"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/36\/3741\/46628143\/ehab499.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/36\/3741\/46628143\/ehab499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:54:47Z","timestamp":1666706087000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/36\/3741\/6352587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,15]]},"references-count":40,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2021,8,15]]},"published-print":{"date-parts":[[2021,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab499","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,21]]},"published":{"date-parts":[[2021,8,15]]}}}